User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8361

Interactions with Platform & by Email *

INTERACTIONS

1171

Unique # Participated *

PARTICIPANTS

251

Responses Validated *

VALIDATIONS

48

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Introduction.....II-1
Biological Drugs Lead the IBD Therapeutics Bandwagon.....II-1
Leading Biological Drugs Approved for Treatment of Crohn’s Disease.....II-1
1$100
   Year of Approval for Leading Drugs in Crohn’s Disease Treatment.....II-2
Impact of the Economic Recession on the Pharmaceutical Industry.....II-2
Recession Brings Drug Development Efforts Under Siege.....II-2
1$100
   Biotech Bankruptcies Rife in the Current Economic Downturn.....II-3
Current and Future Analysis.....II-3
1$100
   Table 1: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease Therapeutics by Disease Type - Crohn’s Disease and Ulcerative Colitis Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-41$350
   Table 2: World 9-Year Perspective for Inflammatory Bowel Disease Therapeutics by Disease Type - Percentage Breakdown of Dollar Sales for Crohn’s Disease and Ulcerative Colitis Markets for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-5
Regional Market Overview.....II-5
United States.....II-5
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs Market.....II-5
1$350
   Key Ulcerative Colitis Drugs in the US (2006).....II-6
Table 3: US Ulcerative Colitis Drugs Market (2007 & 2008): Percentage Breakdown of Prescriptions Dispensed Ranked by Leading Drugs for Asacol, Pentasa, Lialda, Canasa, Sulphasalazine, Colazal, Other Drugs and Generics (includes corresponding Graph/Chart).....II-6
1$350
   Canada.....II-7
Key Challenges Lie ahead.....II-7
Productivity Loss to the Nation.....II-7
Australia.....II-7
1$100
   Japan.....II-8
Europe.....II-8
Increasing Awareness to Drive Market Growth.....II-8
United Kingdom.....II-8
1$100
   Prevalence and Incidence.....II-9
Women More Susceptible to IBD.....II-9
Etiology of Inflammatory Bowel Disease.....II-9
1$100
   Genetic Predisposition.....II-10
Environmental Factors.....II-10
1$100
   IBD – A Health and Social Burden.....II-11
Inflammatory Bowel Disease Types.....II-11
Crohn's Disease (CD).....II-11
Ulcerative Colitis (UC).....II-11
Clinical Manifestations.....II-11
1$100
   Signs and Symptoms.....II-121$100
   Diagnosis.....II-13
Pathogenesis.....II-13
1$100
   Outcomes.....II-14
Treatment Strategies.....II-14
1$100
   Step I (Aminosalicylates).....II-15
5-aminosalicylic acid (5-ASA) Derivatives and Available Brands in the US
  Market.....II-15
Step II (Antibiotics).....II-15
Step III (Corticosteroids).....II-15
1$100
   Available Corticosteroidal Drugs As per Mode of Administration.....II-16
Step IV (Immuno-modifying Agents).....II-16
1$100
   Overview of Select Biological Drugs.....II-17
Infliximab (Remicade).....II-17
Adalimumab (Humira).....II-17
Certolizumab pegol (Cimzia).....II-17
1$100
   Natalizumab (Tysabri).....II-18
Step V (Experimental Medication).....II-18
Experimental Medication Drugs for IBD with Dosage Settings.....II-18
Ileal Pouch recommended in Conditions of Ulcerative Colitis.....II-18
1$100
   Comparing Crohn’s Disease and Ulcerative Colitis.....II-191$100
   Comparison of Characteristics of Ulcerative Colitis and Crohn’s Disease.....II-201$100
   Procter & Gamble Pharmaceuticals Introduces Asacol HD.....II-21
Exagen Diagnostics Introduces eXaIBS Test and eXaIBD Test.....II-21
Cimzia® Receives FDA Nod for Treating Crohn’s Disease.....II-21
Kyorin Pharmaceutical Launches Pentasa Tablets 500.....II-21
1$100
   Xian-Janssen Introduces Remicade, Branded infliximab in China.....II-22
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease.....II-22
Salix and Watson to Launch COLAZAL® Authorized Generic.....II-22
1$100
   GlaxoSmithKline Enters into Partnerships with Biotica, Dynavax, and Archemix.....II-23
Sequenom Buys AttoSense Portfolio and Other Assets from SensiGen.....II-23
Zeria Pharmaceutical to Take Over Tillotts Pharma.....II-23
1$100
   Meridian Bioscience Europe Signs Agreement with BUHLMANN Laboratories.....II-24
Sosei Group Inks Deal with Biocopea.....II-24
UCB Receives FDA Approval for Cimzia.....II-24
1$100
   Regeneron Pharmaceuticals and Sanofi-aventis Extend Global Collaboration.....II-25
Celldex Therapeutics Acquires CuraGen.....II-25
Onyx Pharmaceuticals Acquires Proteolix.....II-25
Roche Acquires ARIUS Research, Inc......II-25
1$100
   Nycomed Inks Agreement with Immunomedics for Veltuzumab.....II-261$100
   Archemix Inks Deal with GlaxoSmithKline.....II-27
Boehringer to Takeover Actimis.....II-27
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals.....II-27
The Asian Institute of Gastroenterology Establishes New facility.....II-27
1$100
   TPG Capital Acquires Axcan Pharma.....II-28
Cosmo Pharmaceuticals Collaborates with Santarus.....II-28
BioLineRx Inks License Agreement with Yissum.....II-28
Salix Pharmaceuticals Secures FDA Approval for APRISO™.....II-28
Omeros Inks Agreement with Affitech.....II-28
1$100
   GlaxoSmithKline Enters into Strategic Alliance with Regulus Therapeutics.....II-29
Roche to Take Over Piramed.....II-29
Evotec Acquires Renovis.....II-29
1$100
   Takeda Pharmaceutical Acquires Millennium Pharmaceuticals.....II-30
GlaxoSmithKline Takes Over Sirtris Pharmaceuticals.....II-30
Boehringer Ingelheim Inks Agreement with Actimis Pharmaceuticals.....II-30
GlaxoSmithKline Enters into a Strategic Alliance with Archemix.....II-30
1$100
   Pipex Pharmaceuticals Buys Oral dnaJP1.....II-31
Emergent BioSolutions Acquires AVANIR’s Anthrax Monoclonal Antibody Collection.....II-31
Ferring Inks License Agreement with Conaris.....II-31
ZymoGenetics and Merck Serono Restructure Their Partnership.....II-31
Evotec Acquires Renovis.....II-31
1$100
   ViroPharma Acquires Lev Pharmaceuticals.....II-32
TPG Capital Inks Agreement to Acquire Axcan Pharma.....II-32
Meyer Pharmaceuticals Inks Agreement with AnGes.....II-32
The School of Pharmacy Enters Into Collaboration with Tillotts Pharma.....II-32
1$100
   Sequenom Inks Collaborative Agreement with SensiGen.....II-33
Evotec Signs Collaborative Agreement with Interprotein.....II-33
Shire Obtains Approval from FDA for LIALDA™ (mesalamine).....II-33
1$100
   Amgen Acquires Avidia.....II-34
Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals.....II-34
1$100
   Abbott Laboratories (US).....II-35
Biogen Idec, Inc. (US).....II-35
1$100
   Cosmo Pharmaceuticals SpA (Italy).....II-36
ChemoCentryx, Inc. (US).....II-36
Dr. Falk Pharma GmbH (Germany).....II-36
1$100
   Eisai Co., Ltd. (Japan).....II-37
Elan Corporation, plc (Ireland).....II-37
Ferring Pharmaceuticals A/S (Denmark).....II-37
1$100
   GlaxoSmithKline plc (UK).....II-38
Johnson & Johnson (US).....II-38
1$100
   Centocor Ortho Biotech, Inc. (US).....II-39
Kyorin Pharmaceutical Co., Ltd. (Japan).....II-39
Merck Serono (Switzerland).....II-39
1$100
   Millennium Pharmaceuticals, Inc. (US).....II-40
Mitsubishi Tanabe Pharma Corporation (Japan).....II-40
Novartis AG (Switzerland).....II-40
1$100
   Otsuka Pharmaceutical Co. Ltd. (Japan).....II-41
Prometheus Laboratories, Inc. (US).....II-41
Shire plc (UK).....II-41
1$100
   UCB SA (Belgium).....II-42
Wyeth (US).....II-42
1$100
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com